Harnessing methods, data analysis, and near-real-time wastewater monitoring for enhanced public health response using high throughput sequencing.

Padmini Ramachandran[1*], Tunc Kayikcioglu[1,2], Tamara Walsky[1], Kathryn Judy[1], Jasmine Amirzadegan[1], Candace Hope Bias[1], Bereket Tesfaldet[1], Maria Balkey, Dietrich EppSchmidt[1,2], Hugh Rand[1], James Pettengill[1], Sandra Tallent[1], Eric Brown[1], Tina Pfefer[1], Ruth Timme[1], Amanda Windsor[1], Christopher Grim[1], and Maria Hoffmann[1]

1. Center for Food Safety and Applied Nutrition, Food and Drug Administration, Office of Regulatory Science, Division of Microbiology, HFS-712, 5001 Campus Drive, College Park, MD 20740, USA.
2. Joint Institute for Food Safety and Applied Nutrition, University of Maryland, 5825, University Research Ct, Suite 1400, College Park, MD, USA.

Address correspondence to:

Padmini Ramachandran
5001, Campus Drive, 4E-019,
College Park, MD- 20740.
Ph no: 3017960610
Email: Padmini.ramachandran@fda.hhs.gov

Abstract

Wastewater-based analysis has emerged as a pivotal method for monitoring SARS-CoV-2 (SC2). Leveraging high-throughput sequencing on wastewater samples facilitates a comprehensive, population-level assessment of circulating and emerging SC2 variants within a community. This study meticulously evaluates the detection performance, variant calling accuracy, and the time taken from sample collection to public data release for wastewater SC2 monitoring. We employed two different SC2 target enrichment panels on Illumina MiSeq and Oxford Nanopore Technologies (ONT) GridION sequencing platforms for a robust analysis. Daily collection of routine raw grab and composite samples took place at a wastewater treatment plant (WWTP) site in Maryland, USA (MD) from mid-January 2022 to the end of June 2022. Total Nucleic Acid (TNA) was extracted from samples and target enrichment was executed using QIAseq DIRECT and NEBNext VarSkip Short amplicon kits, with subsequent sequencing on MiSeq or ONT GridION platforms, respectively. Obtained sequences was analyzed using our custom CFSAN Wastewater Analysis Pipeline (C-WAP). Raw sequence data and detailed metadata were submitted to NCBI (BioProject PRJNA757291) as it became available. Our wastewater data successfully detected the onset of new variants BA.2, BA.2.12, BA.4.6, and BA.5 to the observed population. Notably, Omicron sub-variants were identified approximately a week ahead of publicly available clinical data at the MD ZIP-code level. Variation in quality metrics paralleled the rise and fall of BA waves, underscoring the impact of viral load on sequencing quality. Regular updates of estimated variant proportions were made available on the FDA-CFSAN "Wastewater Surveillance for SARS-CoV-2 Variants" website. In contrast to the median 28-day turnaround for our samples, the lead time from sample collection to public release of raw sequence data via NCBI was remarkably swift, accomplished within a mere 57 hours in this specific exercise. Our processing, sequencing, and analysis methods empowered the swift and accurate detection of SC2 trends and circulating variants within a community, offering insights for public health decision-making.

Keywords

Wastewater, surveillance, SARS-CoV-2, sequencing

Abbreviations

SARS-CoV-2 (SC2), Wastewater treatment plant (WWTP), Total Nucleic Acid (TNA), CFSAN Wastewater Analysis Pipeline (C-WAP).

Introduction

Clinical variant determination of SARS-CoV-2 (SC2) relies on the detection of genomic elements of SARS-CoV-2 by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) based methods from individual patients (1, 2). Clinical analyses are now also being complemented with antibody-based assays that provide an indication of current or previous exposure to SC2 (3). High-throughput sequencing technologies are being used to sequence the SC2 genome from a subset of the infected population (4, 5). This has resulted in a large number of published genomes, and has provided insight into its origins, spread, evolution, and diversity via computational approaches in genomic epidemiology (1). However, inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited testing and/or sequencing capacity or limited community participation, both of which can introduce sampling biases (4).

Utilizing wastewater samples to identify pathogenic human viruses, including SC2, has gained attention as a method for understanding population-level trends in infections (3). SARS-CoV-2 RNA concentration in wastewater has been shown to convey regional infection dynamics and provides less biased abundance estimates than clinical testing (1, 3). As SC2 continues to spread and evolve, early detection of emerging variants is critical for orchestrating public health interventions.

There are many factors limiting wastewater-based genomic surveillance of pathogens. For example, despite the promising success of a few studies (6, 7), it is still challenging to understand how well wastewater-based epidemiology can identify the genetic diversity of SARS-CoV-2 in each population and how this relates to known viral diversity of clinical cases. This is especially important as new variants emerge (1). Many challenges also lie in the accurate identification of SC2 variants and estimation of their abundance in mixed population samples such as wastewater. While deep sequencing without prior amplification may be efficient for viruses that reside in high quantity in plasma, in a mixed population of

variants and a complex environmental matrix like wastewater, sequencing without amplification is impractical (8). For wastewater-based viral detection, implementation of a multiplexed target enrichment panel is necessary. However, there are challenges in the analysis of sequencing reads from target enrichment panels for accurate identification of multiple variants in a single sample. Here we use an analysis pipeline, the CFSAN Wastewater Analysis Pipeline (C-WAP, https://github.com/CFSAN-Biostatistics/C-WAP), for identification and abundance estimation of circulating variants. As SC2 evolves and new variants arise, continued monitoring for emerging variants will be an important component of public health efforts (9). As the virus evolves, enrichment kits, databases of variants, and detection methods will also need to evolve and be re-evaluated to ensure the best possible methods are in use.

The application of high-throughput sequencing for the rapid identification and surveillance of pathogens has recently become common place in public health systems (10-12). The SC2 pandemic has helped bring WBE to the forefront of community-scale pathogen surveillance (7, 13). Here, we describe how monitoring wastewater from urban areas can be used to detect the arrival of emerging SC2 variants of SC2 in a chosen sewer shed. This study adapted two different target enrichment panels, initially designed for clinical samples, for application in wastewater samples. Additionally, both protocols were optimized and published to protocols.io (14). The study established critical quality control checkpoints within the laboratory workflow and on the analysis of sequence data derived from a mixed population of wastewater samples. The evaluation encompassed the detection performance and variant calling accuracy using two different SC2 target enrichment panels, covering 99.16 +/- 0.58% of the SC2 genome conducted on both Illumina MiSeq and Oxford Nanopore Technologies (ONT) GridION sequencing platforms. A crucial aspect explored was the turn-around-time from sample collection to public data release, recognizing its significant public health impact. The findings demonstrated the effectiveness of high-throughput sequencing of SC2 genomes from wastewater. The incorporation of precision analysis

tools, such as C-WAP, facilitated the early detection of emerging variants of concern in wastewater samples.

In summary, this study emphasizes the need for community-based surveillance, complemented by rigorous and comprehensive analysis and investigation. The thorough analysis when assessing the performance of enrichment panels employed here, considering the interplay between the enrichment panel itself and the specific sequencing technology, is extremely valuable. This study utilized a comprehensive wastewater analysis pipeline, crafted for real-time surveillance of mixed population samples that took into consideration several aspects of targeted amplicon-based sequencing, implemented strict QC measures to avoid false positives, critically assessed emerging variants by looking at the characteristic mutations, and evaluated several genome coverage metrics across the genome. The insights gained from this study offer valuable lessons applicable to wastewater surveillance methodologies targeting emerging pathogens.

Materials and Methods

Sample collection

Wastewater samples were collected from a wastewater treatment plant in Maryland from January 12, 2022, to June 28th, 2022. The raw wastewater was collected daily from January 12th to February 28th, 2022 as two 1-liter raw grabs (2 biological reps) in Nalgene bottles and stored at 4°C. The samples were retrieved weekly and subsequently stored at 4°C until use. From January 12 to February 28th, 2022, raw wastewater grab samples were extracted and analyzed as individual samples with 2 biological replicates for each day resulting in 14 samples per week.

Composites were collected as 1L grabs from Feb23rd 2022 till June 28th, 2022. Composites were aliquoted from the auto sampler (auto sampler has a collection interval of 30 mins for 24hrs) as two-1L grabs in Nalgene bottles and stored at 4°C until use. Each biological replicate per week after pooling was

137 then split into three 40mL technical replicates, resulting in six samples per week (Supplementary table 1,
138 Schematic Fig 1). The complete workflow for this study is described in detail in Fig1.

139 **Total nucleic acid extraction and SARS-CoV-2 RT-qPCR detection**

140 Sample concentration and total nucleic acid extraction was performed on the pooled
141 wastewater using Maxwell RSC Enviro TNA Kit (Promega, Madison, WI USA) following manufacturer's
142 recommendations. The extracted total nucleic acid was stored at -20 C for short term (a week) to
143 process for the cDNA generation and RT-qPCR. After the necessary amount was aliquoted, the TNA was
144 stored at -80 C for long term storage. The detailed protocol has been published in
145 dx.doi.org/10.17504/protocols.io.rm7vzy52xlx1/v1.

146 The quantification of SARS-CoV-2 in wastewater was performed utilizing the Promega GoTaq®
147 Enviro Wastewater SARS-CoV-2 System, which targets the N1 gene (Promega, Madison, WI USA)
148 following manufacturer's recommendations. This includes guidance for converting RT-qPCR output into
149 calculated viral genome copies per liter.

150 **DNA digestion and cDNA synthesis**

151 Genomic DNA was digested with ezDNase (Invitrogen, Waltham, MA USA) with protocol
152 modifications. Reaction cocktails consisted of 10uL template TNA, 2µL nuclease free water, 1µL
153 ezDNase™ buffer, and 1 µL ezDNase™ enzyme. Reactions were then digested at 37°C for 5 minutes.
154 Digestion was stopped by addition of 1µL 10mM DTT and a 5-minute incubation at 55°C. Reactions were
155 chilled on ice for at least 1 minute before proceeding to cDNA synthesis.

156 cDNA was synthesized from the purified RNA with the Superscript IV Reverse Transcriptase
157 (Invitrogen, Waltham, MA, USA) with modifications to the manufacturer protocol. Primer annealing was
158 carried out with 1µL 50µM random hexamers, 1uL 10mM dNTP mix, 1µL DEPC-treated water, and 10µL

159 template RNA. Reactions were incubated at 65°C for 5 minutes, then incubated on ice for at least 1
160 minute. The Reverse Transcriptase reaction mix was prepared with 4µL 5x SSIV Buffer, 1 µL 100mM DTT,
161 1µL RNaseOUT™ Recombinant RNase Inhibitor, and 1uL SuperScript IV Reverse Transcriptase (200U/µL)
162 and then added to the chilled primer-annealed RNA. Reactions were then incubated at 23°C for 10
163 minutes, 50°C for 30 minutes, then 80°C for 10 min. cDNA was stored at -20ºC until use.

164 **Selection of enrichment panels for this study.**

165 October through December 2021, we evaluated some commercially available SC2 enrichment
166 panels. Enrichment panels for assessment were chosen based on multiple criteria. Our main objective
167 was to ensure even coverage across the genome; therefore, we chose kits with tiled amplicon across the
168 entire SC2 genome and simple library preparation of these amplicons to achieve rapid, simple, and cost-
169 effective sequencing. Read lengths of the amplicon to adapt to both short read sequencing chemistry
170 and long read sequencing chemistry were also considered. The commercial enrichment panels that were
171 assessed initially included Midnight FREED primers (1200 bp long amplicons with Oxford Nanopore
172 library and sequencing) (15), SWIFT SNAP additional genome coverage panel (150 bp long amplicons
173 with Illumina MiSeq sequencing) (16), NEBNext VarSkip Short primers (560 bp long, with possibility of
174 sequencing in both Illumina and ONT platform) (17), and QIAseq DIRECT enrichment panel (250 bp
175 amplicons with Illumina MiSeq sequencing). Based on the ease of generating the amplicons, ease of
176 library preparation and adaptability of the amplicons with different sequencing platforms we chose two
177 enrichment panels for this study that are discussed in detail in this manuscript, QIAseq DIRECT and
178 NEBNext VarSkip Short (NEB VSS). The QIAseq DIRECT panel has 222 primer pairs with average amplicon
179 length of 250 bp while the NEB VSS panel has 74 primer pairs with an amplicon length of about 560 bp,
180 on average.

181 **QIAseq DIRECT SARS-CoV-2 enrichment panel**

cDNA amplification was performed using QIAseq DIRECT SARS-CoV-2 enrichment panel following manufacturer's protocols. After the emergence of variant BA.5, (June 13th, 2022), the manufacturer distributed an auxiliary primer set as a spike-in to the existing protocol. The samples from May 17th and onward were amplified using the spike-in to the enrichment panel. The detailed protocol is publicly available at **dx.doi.org/10.17504/protocols.io.rm7vzy39rlx1/v4**

NEB VSS SARS-CoV-2 enrichment panel

cDNA amplification was performed utilizing the NEB VSS SARS-CoV-2 enrichment panel following manufacturer's protocol. Due to the emergence of BA.2.12, there was a change in the primer version from VSS v1a to VSS v2a starting from the week of March 1st. There was also a spike-in introduced in the primer pairs as an update to the kit due to the emergence of BA.5. The samples from the week of May 11th and onward were amplified using the enrichment panel with spike-in. The detailed protocol is publicly available at **dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2**

High throughput Sequencing

QIAseq DIRECT amplicons were sequenced using Illumina MiSeq (Illumina, San Diego, CA). NEB VSS amplicons were sequenced using Oxford Nanopore GridION sequencing (Oxford Nanopore Technologies, Oxford, UK). Every sample (n = 182) was amplified using both QIAseq DIRECT SARS-CoV-2 enrichment panel and NEB VSS SARS-CoV-2 panel (n=364). The libraries of NEB VSS amplicons were prepared using ligation sequencing kit (Oxford Nanopore Technologies Ligation Sequencing Kit (SQK-LSK109), Cambridge, UK) as described in the publicly available protocol **dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2** run on a R.9.4 flow cell (R9.4.1) for 72 h.

Data analysis, quality metrics and variant calling

To address the many challenges in accurate identification of multiple variants, we further customized our analysis tool CFSAN Wastewater Analysis Pipeline (C-WAP)(9) . The latest version of C-WAP is now available on GitHub https://github.com/CFSAN-Biostatistics/C-WAP. Briefly, sequences are aligned to the reference genome (Wuhan-Hu-1, NCBI assembly ASM985889v3, NC_045512.2) using Bowtie2 (v2.4.5) and Minimap2 (v2.24), followed by adapter trimming and quality filtering in iVar (v1.3.1). When processing Illumina data, the iVar trim function was configured to discard the adaptor sequences; filter sequences below a quality score of 20 (default); filter reads that are shorter than 50% of the average length of the first 1000 reads (default); and use a 4 bp sliding window (default). For ONT data, iVar trimming is configured the same, with the exception that all sequences are retained (quality score filter of 1), effectively preserving the filtering of reads to a quality score of 7 performed by Guppy, the default intrinsic base caller onboard ONT MinKNOW sequencing software.

C-WAP provides three methods for variant calling: Kraken2 (v2.1.2) / bracken (v2.7), kallisto (v0.48), and a Samtools (v1.15) pileup piped into Freyja (v1.4.4). Bracken is a Bayesian abundance estimator based on Kraken2 sequence calls. A comprehensive list of dependencies for C-WAP is available in the GitHub readme.

C-WAP takes into account the number of raw reads that align to the reference sequence and pass filter, *i.e.*, read lengths after adaptor trimming ≥30 and minimum read quality ≥20 within a sliding window of width 4 bases. C-WAP outputs a comprehensive report along with several distinct quality metrics (Table 1). These include the percent of reads aligned to SARS-CoV-2 genome, coverage depth of the sequencing reads at every genomic coordinate of the SARS-CoV-2 genome, read quality, coverage depth over the entire breadth of the SARS-CoV-2 genome, absolute counts of genomic coordinates with less than 10X coverage or no coverage, scaled counts of genomic coordinates that with less than 10X coverage or no coverage, and variant abundance estimation using Freyja, kallisto, and Kraken.

Characteristic mutations for several variants, including variants B.1.617.2, BA.1, BA.2, BA.3, BA.4, and BA.5 (18), the variants of concern most relevant to the timeframe of this study, were extracted from the C-WAP report (Supplementary table 2). The table is generated under the assumption that the presence of a variant requires the detection of all mutations of a particular variant. The characteristic mutations which support the presence of a particular variant are indicated in the respective column of the table. A detected mutation table with detection frequency and p-values for every alternate base in each position is generated where only the genomic coordinates with at least 10X coverage were considered.

Concordance correlation coefficient

A concordance correlation coefficient (CCC) with Euclidean distance was used to evaluate the levels of pairwise agreement among the abundance estimation methods for both amplicon panels, NEB VSS and QIAseq DIRECT. It was adapted by Cui et al. (19) from Lin's concordance correlation coefficient for agreement studies with microbiome compositional data. CCC has values between -1 and 1, where -1 indicates a perfect disagreement, 1 indicates a perfect agreement, and 0 indicates a complete absence of agreement between the two abundance estimation methods. Bayes-Laplace Bayesian-multiplicative replacement method (20) is used to impute zero relative abundances on the entire dataset before computing CCC values. A bootstrap method with sample size of 5,000 is used to build a 95% confidence interval for each CCC estimate.

To understand the agreement between the variant callers on real world data, in the amplicon panels used in this study, for the CCC analysis a subset of (n= 11) samples were chosen. The sample chosen for this analysis were samples collected on the week of May 5th, 2022 (6 samples) and the week of June 28th, 2022 (5 samples). The 11 samples/22 sequences (with each sample being amplified with NEB VSS and QIAseq DIRECT and sequenced in ONT and Illumina MiSeq respectively) were chosen based

on sequence reads having uniform coverage across the genome, good breadth versus depth metric and higher percent covid hits. For the week of May 5th samples, the amplicon panels lacked the spike-in primers. In this instance, the basic panel successfully identified the circulating variants at the time. For the June 28th samples, both amplicon panels were equipped with updated spike-in primers capable of detecting the prevailing variant circulating at that time.

Dashboard display

Sequencing data that passed QC assessment (category A and B, Table 1) were submitted in real time to National Center for Biotechnology Information (NCBI) for active monitoring for circulating variants. To facilitate the sharing of information about progress on this sequencing effort, FDA developed a dashboard that graphically presented findings from this project (21). Active support and updates to the dashboard ended on June 30, 2023, the final state of the dashboard remains available at https://www.fda.gov/food/whole-genome-sequencing-wgs-program/wastewater-surveillance-sars-cov-2-variants.

Data visualization:

Downstream data analysis and visualization were carried out in RStudio (v.1.3.1093) using the following R packages: ggplot2 (v3.4.1), dplyr (v1.1.0), reshape2 (1.4.4), ggh4x, and stringr (v1.5.0).

Data availability:

Data generated in this study were deposited in the NCBI BioProject database under the BioProject accession number PRJNA757291.

Results

SARS-CoV-2 viral load and relationship to clinical cases:

The viral load of SARS-CoV-2 in wastewater was assessed throughout the time course of this study to understand the impact of viral burden levels and dynamics on amplicon sequencing success and output. Computed viral load, calculated from RT-qPCR on samples taken from the wastewater treatment plant, ranged from 350 genome copies/L to 99,840 genome copies/L, with fluctuations that mirrored variant waves (Fig 2). To understand the relationship of wastewater-based surveillance burden estimations and actual clinical reporting, clinical data were plotted against the viral genome copies/L over time (Fig 2, Supplementary table 3). The rolling 7-day average of new clinical SARS-CoV-2 cases for the two ZIP codes (21157 and 21158) served by the wastewater treatment plant was extracted from MD department of Health website, https://opendata.maryland.gov/Health-and-Human-Services/MD-COVID-19-Cases-by-ZIP-Code/ntd2-dqpx/data_preview. When compared to the reported clinical cases, which ranged anywhere between 1 case per week to 866 cases per week, we observed a seemingly lower rate of clinical testing from March 2022 onward (Fig 2).

Percent reads aligned vs genome copies of SARS-CoV-2

Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT-qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period, emphasizing the dependence of high quality SC2 genome amplicon sequencing on circulating viral load. The lowest percent reads aligned were observed during February and March 2022 when SARS-CoV-2 was relatively scarce, but percent reads aligned increased beginning in April, with the surge of the Omicron variants, through the end of the monitoring period for this study, June 2022.

Comprehensive QC metric analysis

To characterize sequencing performance, C-WAP outputs a comprehensive report with several distinct quality metrics including the aforementioned percent reads aligned to the SC2 genome, coverage depth of the sequencing reads at every genomic coordinate of the SC2 genome, read quality, read counts for each primer pair of the amplicon panel, coverage depth over the entire breadth of the SC2 genome, absolute counts of genomic coordinates with less than 10X coverage or no coverage, scaled counts of genomic coordinates that with less than 10X coverage or no coverage, and variant abundance estimation using Freyja, kallisto, and Kraken (Supplementary report 1, 2). The following sections includes detailed results of the metrics considered by C-WAP for the samples discussed in the study.

Coverage depth vs coverage breadth:

We compared sequencing depth versus breadth of the SC2 genome for both amplicon kits, QIAseq DIRECT and NEB VSS. The ideal sequencing run would have the maximum sequencing depth (greatest number of reads aligned) over the entire breadth (100%) of the genome, indicating even coverage over all genomic coordinates. Across the time course of this study, the coverage depth versus breadth for each amplicon kit used for each month of wastewater surveillance (Fig 4) improved as we optimized our sample collection and sequencing methods, with values for the metric converged towards the ideal in June compared to January. Comparison of the amplicon panels shows that the NEB VSS panel has lower genome coverage when compared to the QIAseq DIRECT panel for January and February, but by June the breadth versus depth for all sequencing runs are similar between amplicon kits.

Genome coverage across ORF1ab, S, M, and N genes of SC2 genome:

Calculations of absolute and scaled coverage for each nucleotide site within all SC2 genes (5’ UTR, ORF1ab, S, ORF3a, E, M, ORF6, ORF7ab, ORF8, N, ORF10, 3’UTR) was extracted from the C-WAP

report. Genome coverage for four key genes, namely ORF1ab, S, M and N genes, was used to detect characteristic mutations of the variants from January through June 2022 (Fig 5) during this study. Both NEB VSS and QIAseq DIRECT enrichment panels had more under-covered (<10x) sites within the S gene when compared to coverage of the remaining three key genes. 255 samples enriched by QIAseq DIRECT showed under-coverage in the S gene, versus an average of 166 samples for the other three key genes, while 109 samples enriched by NEB VSS showed S gene under-coverage, versus an average 92.3 samples? for the other three genes. An overall poor performance of QIAseq DIRECT on the M gene was observed across all months of sampling, when compared to NEB VSS, with the average scaled M gene under-coverage across all QIAseq DIRECT samples 117% greater than that of NEB. In contrast, the NEB VSS amplicon panel was observed to have more under-covered sites on ORF1ab and N genes across all months of sampling—78% and 13% greater average scaled under-coverage, respectively.

Concordant Correlation Coefficient

To further assess performance and agreement between the two amplicon panels and the variant callers used in this study, we computed concordant correlation coefficients (CCC) to compare the performance of the top two variant callers (9), Freyja and kallisto, using a subset of high-quality sequenced samples, determined by having good QC metrics with uniform coverage across the genome (Fig 6). The CCC was positive for each kit, though under 0.25 for each, indicating mild agreement between the variant callers (Fig 6). The CCC between the variant callers was relatively higher for QIAseq DIRECT samples (0.2113 as opposed to 0.0102 for NEB VSS) and had a 95% confidence interval that did not span 0, indicating a statistically significant agreement. In contrast, the CCC for NEB VSS samples had a 95% confidence interval spanning 0, indicating there is likely no relationship between the variant detection calls by Freyja and kallisto. Accordingly, this suggests that for NEB VSS samples with GridION sequencing, one variant caller may be a better choice than the other to produce the most accurate

results, while for QIAseq DIRECT samples with MiSeq sequencing, the choice of variant caller may be less important.

Circulating variant estimation:

During the sampling period, our surveillance system not only captured the major and minor variants circulating within the community but also detected the emergence of new variants. We combined the variant results from all 364 sequences from 182 samples, agnostic to the kit and sequencing platform used, to observe the general trend of circulating variants using Freyja as its database is updated more frequently. The MD wastewater samples clearly identified the emerging variants of concern like BA.1, BA.2.12, BA.4.6 and BA.5 from January 2022 through June 2022 (Fig 7, Supplementary Fig 1). Omicron BA.1 was the dominant circulating variant when the wastewater sampling began in January 2022. January 29th samples showed signs of emergence of BA.2, and dominant detection of BA.2 was observed from March 30th, 2022. BA.2.12 was detected starting from end of March 2022, followed by BA.4 and BA.5 in mid-May, and dominantly detected starting end of May 2022. We also observed traces of BA.4.6 in mid to late June, agreeing with the onset of BA.4.6 in clinical cases in Maryland.

Early detection of BA.2:

The BA.2 lineage was first detected in samples collected on January 29th, 2022, and again on January 31, 2022 with both the NEB VSS and QIAseq DIRECT enrichment panels. The first clinical reporting of the BA.2 lineage in the entire state of MD by the CDC was on January 27th, 2022 (variant data is not available per zip code). To verify the early detection of BA.2 in these wastewater samples, every mutation identified using both enrichment panels was examined for six days (January 27th–February 1st) surrounding the first purported appearance of BA.2 (Fig 8A). Detected mutations for each day were categorized based on their presence/absence in BA.1 and BA.2 lineage sequences. Mutations

shared between BA.1 and BA.2 in the characteristic mutation table generated by C-WAP were marked as "BA.1 or BA.2" mutations. Identified mutations that are not present in BA.1 were categorized as "Incompatible with BA.1" and mutations only present in BA.2 were categorized as "BA.2 diagnostic mutations." All mutations detected were considered statistically significant (p-value < 0.05) and present in at least 10 sequencing reads.

The prevalence of these three mutation categories on both enrichment panels on each of four days in January and in March 2022, when BA.2 was well established, was visualized by showing the frequency of each mutation and its place in the SARS-CoV-2 genome (Fig 8B). The landscape of relevant mutations on both early BA.2-detection days (January 29th and 31st) is highly similar to the pattern of mutation prevalence and detection in March, when BA.2 was consistently present in both wastewater and clinical samples. BA.2 diagnostic mutations were detected with frequencies up to at least 0.5 in some samples, while most detected BA.1-incompatible mutations were present with frequency of 0.25 or greater.

In contrast, the mutations detected on January 28 include no BA.2 diagnostic mutations and BA.1-incompatible mutations are largely present in low frequency. This shows the presence and frequency of BA.2 diagnostic mutations and the overall profile of mutations observed at the early detection dates, January 29th and 31st, mimic that from a later sample, from March 30th, when BA.2 was known to be present in the WWTP service area.

Realtime submission of surveillance data:

After the sequencing protocol was optimized and QC metrics were in place, we made an effort to quantify the minimum time from sample collection to sequence analysis and release. Composite grabs for the week of June 28th, 2022, were collected at 6 am from the treatment plant and the time to process these samples was recorded. Total nucleic acid extraction, cDNA synthesis, amplification using

NEB VSS enrichment panel, and loading of the libraries on to Oxford Nanopore GridION took 30hrs. After 16hrs, we had collected sufficient sequence data that passed QC to detect all the characteristic and diagnostic mutations for BA.5. Data analysis using C-WAP, upload of this data to NCBI, and display on the dashboard took 11 hrs. The total turnaround time from sample collection to dashboard display was 57hrs.

Discussion

Six months of wastewater surveillance, made possible through the partnership with a wastewater treatment plant in Maryland, detected new variants as they emerged along with major and minor variants circulating in the community. From a clinical perspective, this level of resolution of community disease dynamics could underpin traditionally monitored clinical testing and help public health officials to serve communities more efficiently. A wastewater surveillance system fills data gaps for areas where clinical testing and surveillance may be limited, including underserved communities with limited access to testing sites.

The laboratory and bioinformatic methods employed in this study confidently detected multiple circulating SARS-CoV-2 (SC2) variants in wastewater samples using amplicon-based targeted enrichment panels. Several enrichment panel kits were evaluated, but only two, the QIAseq DIRECT and NEB VSS panels were pursued as the best options for wastewater samples.

The viral load in wastewater, when compared to the clinical cases, indicated a low rate of clinical testing as the pandemic began to wane (Fig 2). In other words, there were higher levels of SC2 in the community, based on wastewater analysis, than were being estimated based on reports from clinical testing. This is perhaps because at-home test kits became widely available within the community around the same time as this study commenced. From wastewater data, it is evident that clinical testing did not fully capture the wave of infections during early April to June 2022 (Fig 2). A limit of detection with

genome copies/L to the SC2 hits was not established and so all samples were sequenced regardless of RT-qPCR result (22). Having strict QC measure in place helped us to overcome this lack of a robust RT-qPCR LOD threshold and eliminate some poorly performing samples attributed to the lower genome copies/L.

A main goal of wastewater surveillance is to track emerging and circulating variants at a community level and hopefully provide an early warning signal of emerging and increasing infections without the need for community clinical information. For example, we detected BA.2 ahead of the clinical findings for the state. It is important to note that the variant calls are published only at the state level by CDC, not at the ZIP code level. Here we detected BA.2 at the community level covering two ZIP codes 14 days ahead of BA.2 variant calls published by CDC at the state level for Maryland. This emphasizes an ability of community level surveillance using wastewater: enabling a more focused public health local response during a pandemic.

In SC2 variants, mutations across the S-gene play a crucial role in variant calling. Research is ongoing to elucidate the mechanisms involved but the mutations may boost infectivity and transmissibility through increased spike density, enhanced cleavage and host cell uptake, and increased viral load and ability to evade host immune responses (23). Mutations may also interfere with laboratory testing and complicate epidemiological monitoring by interfering with detection in sequence-based tests. If a mutation occurs in the part of the viral genome assessed by a PCR test, the sample may result in gene “dropout.” We observed a significant drop in coverage of the S gene with the NEB VSS panel on the week of May 11. For this same week, RT-qPCR of these samples had 90,587 genome copies/L indicating a high SC2 viral load in the community (the range of genome copies for the duration of this study was from 350 genome copies/L to 99840 genome copies/L). The significant drop in S gene coverage raised concerns and the vendor was contacted and spike-in to the primer pool 1 was obtained to overcome the dropout due to the rise of BA.5 sub variants. When we repeated the amplification and

sequencing of samples from the week of May 11 using the primer spike-in (NEB VSS), we observed improved coverage on the S gene because of the three characteristic mutations (S:S371F, S:T376A, S:D405N) detected with the spike-in that were not detected with the original primer panel.

A diagnostic mutation of BA.5 in the M gene (M:D3N) was first detected the week of May 11 with QIAseq DIRECT enrichment panel. This same mutation was not detected until the week of June 1 using NEB VSS enrichment panel. A spike-in for the QIAseq DIRECT enrichment panel was introduced from the week of June 13. The spike-in primers in the QIAseq DIRECT panel had a slightly higher concentration of primers compared to its original panel across this region (23082-23144 bp). While there was not a full dropout in this region (23082-23144 bp), the observed coverage was lower, and the concentration of the primers (QIAseq_170_RIGHT, QIAseq_172_LEFT, and QIAseq170-2_RIGHT) were increased to provide more uniform coverage within that gene. Since mutations may affect detection, treatment, and prevention, it is important to identify strains correctly to direct public health containment strategies (5). To address this type of limitation, there are studies that incorporate targeted sequencing of only variable regions of interest in the genome, particularly those regions that contain mutations unique to specific variants of concern (5). In addition, there are studies that apply PCR amplifying, cloning, and sequencing a 1.5□kb region of the spike protein gene to confirm the linkage of mutations of interest to understand all the circulating variants in a complex sample (24). While these approaches provide valuable information on a very targeted genomic area where mutations are known to occur, mutations at other genomic coordinates, which might be indicative of emergent variants and variants, will not be obtained.

In practice, when a diagnostic or surveillance test is based on targeted amplification, for it to be able to detect variations in the genome of pathogens, it is necessary to regularly update the primer pairs and/or alter the target regions used in the detection systems or use several target genes of the infectious agent in the same test reaction to minimize the risk of false negative results (5). Both

455 enrichment panels evaluated in this study consistently updated the primer pairs for the detection of
456 circulating variants. In an ARTIC primer approach where entire primer versions are updated, the
457 emergence of new variants renders any remaining primers obsolete (25, 26). This stands in contrast to
458 the spike-in approach, where the spike-in is introduced to the original pools, minimizing the
459 regeneration of old primers and revitalizing their performance. Many enrichment panels contain
460 degenerate primer designs of polymorphic regions of the genome to allow more robust amplification of
461 variable strains. Also, strategically designed primer pairs for consistent coverage are essential for highly
462 evolving genomes like SC2 (5). Keeping the challenges of uniform coverage within the targeted site,
463 primer binding efficiency, and adaptation to several sequencing approaches in mind, choosing a suitable
464 target enrichment panel and pairing it with the suitable library preparation kit based on the sequencing
465 platform may play a critical role in identifying the circulating and emerging variants.

466 When we assessed genome coverage metrics for four key genes (ORF1ab, S, M and N genes),
467 both QIAseq DIRECT enrichment panel and NEB VSS enrichment panel had substantial under-covered
468 regions on the S gene when compared to the other three genes. In the NEB VSS SARS-CoV-2 enrichment
469 panel, there are 10 primer pairs targeting the S gene (genome coordinates:21563-25384) with an
470 overlapping primer pair included to enable detection of BA.5 specific mutations. The S gene is the most
471 mutation-prone region of SC2 genome, which means that primer binding sites for this gene can play a
472 major role in variant calling performance on a mixed sample like wastewater. For the M gene, the
473 QIAseq DIRECT enrichment panel had lower coverage across all months when compared to NEB VSS
474 enrichment panel (Fig 5). Two characteristic mutations within the M gene used to assess all Omicron sub
475 variants correspond to primer binding regions in the QIAseq DIRECT enrichment panel, while neither
476 mutation is in a primer binding region for NEB VSS. The QIAseq DIRECT enrichment panel has more
477 amplicons with more primer pairs (222 primer pairs total, whereas NEB VSS panel has 74 primer pairs)
478 and is more suitable for short read sequencing (~250bp amplicon length) which results in high coverage

479 across the genome. But there is a greater chance of mutations occurring in a primer binding site,
480 especially for rapidly evolving genes, such as the S gene. The NEB VSS primer panel somewhat mitigates
481 this with longer amplicon length (~560bp) and fewer primer pairs. Continuous evaluation of current and
482 emerging target enrichment panels is essential to accurately detect existing and evolving SC2 variants
483 from wastewater.

484 During the development of C-WAP, a critical performance assessment of various variant callers
485 on *in silico* reads of mixed variants revealed that Freyja was the most suitable variant caller on short
486 read data and kallisto was the most suitable variant caller for the long read data (9). The concordant
487 coefficient analysis on our real-world data agreed with those previous findings (Fig 6) However, to
488 solidify these conclusions, further investigations are warranted, particularly with a larger sample size.
489 Additionally, considering the evolving nature of viruses, future studies should explore the impact of
490 different amplification kits on variant calling accuracy.

491 We tested the feasibility of the real time submission of data to support the public health
492 response. Real time submission and publication to the dashboard within 57 hours was possible because
493 of real-time long read sequencing through Oxford Nanopore GridION. After just 16 hrs of sequencing,
494 there was enough accumulated sequencing depth data that passed QC to provide high confidence in the
495 accuracy of variant calling. Even though the run time in GridION was chosen to be 72hrs, most of the
496 data were collected in the initial 20hrs after sequencing started. However, to ensure high quality data,
497 we multiplexed only 9 samples per flow cell on GridION, compared to 28-32 possible samples on
498 Illumina MiSeq. The Illumina MiSeq, despite its inherent speed limitations, presents promising prospects
499 for near-real-time applications when Read1 data is being used. While just the Read1 data can
500 successfully pass all quality control (QC) metrics, there is a subsequent delay of up to 24 hours for
501 uploading the sequence data from a paired-end run, which might be advantageous for maximizing
502 quality scores. It is important to understand the complexity associated with multiplexing samples per

503 flow cell, a factor that may necessitate adjustments based on the viral load. Our team has established
504 best practices for the efficient collection, organization and surveillance of sequence data (21). Analyzing
505 the turnaround time from sample collection to NCBI data release revealed a median duration of
506 approximately 28 days for the samples in this study. However, this exercise has illuminated the potential
507 for real-time data submission, enabling immediate surveillance insights. Regardless of the sequencing
508 technology, near real time data submission is possible through wastewater surveillance which will
509 support community level decision making easier during pandemic. Incorporation of automated liquid
510 handling robots could further reduce time from sample receipt to data publication.

511 Due to the dynamic and swiftly evolving nature of SARS-CoV-2, our dedication to real-time
512 dashboard updates and the dissemination of optimized protocols to the wastewater surveillance
513 community, this study has some limitations. One limitation was the inability to delve into the genuine
514 distinctions in raw wastewater and composites beyond a one-week sample analysis period where we
515 explored both raw wastewater grabs (February 23rd to February 28th) and composite grabs (February
516 23rd to February 28th). We needed to investigate the feasibility of weekly sample pooling as a strategy
517 (February 28th, 2022, and onwards) to reduce the processing workload in our laboratory, and when we
518 did not find any differences in the viral load and other QC metrics when the sequences, regardless of
519 enrichment panel, were analyzed from that week, we proceeded with weekly sample pooling.
520 Additionally, we were constrained in exploring the potential benefits of multiplexing varying sample
521 quantities on GridION flow cells to comprehend sequencing depth. This study is also limited by not
522 including an evaluation of other commercially available enrichment panels, such as ARTIC V4 or Resende
523 (26, 27). Moreover, the study was hindered in its capacity to investigate spike-in studies with known
524 concentration of the virus in various matrices, which are essential for establishing a true limit of
525 detection.

The two amplicon panel kits demonstrated robust efficacy in detecting both circulating and emerging variants in wastewater samples. The two panels used in this study underwent sequencing on two distinct platforms, and to ensure accurate assessment, we established customized quality control (QC) metrics using C-WAP. Regarding variant calling, both enrichment panels successfully detected the presence of BA.2 on January 29th, 2022, samples and consistently detected other circulating variants throughout the study duration. The comprehensive analysis employed in this study emphasizes the importance of evaluating the performance of any enrichment panel in conjunction with the chosen sequencing technology.

Conclusion

We supported the public health response effectively during the pandemic by constant method optimization, updates to the wet lab protocol, updates to the databases for the variant calling, comprehensive analysis, pairing up the enrichment panel with suitable sequencing technology, appropriate variant callers used throughout the surveillance, and the efficient updates of a dashboard. Finally, as seen here, our findings highlight the value of extensive data analysis metrics, method optimization, and a near-real-time public health response. These insights can serve as valuable considerations for decision-making in the establishment of new surveillance initiatives, especially those involving mixed samples and complex sample types such as wastewater. In essence, this study provides a blueprint for thoughtful consideration of various metrics when conducting surveillance using target enrichment panels, offering valuable lessons that can inform the development of future surveillance studies.

References

1. Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature. 2022;609(7925):101-8.

549 2. Ahmed W, Bertsch PM, Bibby K, Haramoto E, Hewitt J, Huygens F, et al. Decay of SARS-CoV-2
550 and surrogate murine hepatitis virus RNA in untreated wastewater to inform application in wastewater-
551 based epidemiology. Environ Res. 2020;191:110092.
552 3. Achak M, Alaoui Bakri S, Chhiti Y, M'Hamdi Alaoui FE, Barka N, Boumya W. SARS-CoV-2 in
553 hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection
554 technologies. Sci Total Environ. 2021;761:143192.
555 4. Fontenele RS, Kraberger S, Hadfield J, Driver EM, Bowes D, Holland LA, et al. High-throughput
556 sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants. Water Res.
557 2021;205:117710.
558 5. Smyth DS, Trujillo M, Gregory DA, Cheung K, Gao A, Graham M, et al. Tracking cryptic SARS-CoV-
559 2 lineages detected in NYC wastewater. Nat Commun. 2022;13(1):635.
560 6. Farkas K, Hillary LS, Malham SK, McDonald JE, Jones DL. Wastewater and public health: the
561 potential of wastewater surveillance for monitoring COVID-19. Curr Opin Environ Sci Health. 2020;17:14-
562 20.
563 7. Aguiar-Oliveira ML, Campos A, A RM, Rigotto C, Sotero-Martins A, Teixeira PFP, et al.
564 Wastewater-Based Epidemiology (WBE) and Viral Detection in Polluted Surface Water: A Valuable Tool
565 for COVID-19 Surveillance-A Brief Review. Int J Environ Res Public Health. 2020;17(24).
566 8. Hamouda M, Mustafa F, Maraqa M, Rizvi T, Aly Hassan A. Wastewater surveillance for SARS-
567 CoV-2: Lessons learnt from recent studies to define future applications. Sci Total Environ.
568 2021;759:143493.
569 9. Kayikcioglu T, Amirzadegan J, Rand H, Tesfaldet B, Timme RE, Pettengill JB. Performance of
570 methods for SARS-CoV-2 variant detection and abundance estimation within mixed population samples.
571 PeerJ. 2023;11:e14596.
572 10. Wang Y, Hu X, Yang L, Chen C, Cheng H, Hu H, et al. Application of High-Throughput Sequencing
573 Technology in the Pathogen Identification of Diverse Infectious Diseases in Nephrology Departments.
574 Diagnostics (Basel). 2022;12(9).
575 11. Suminda GGD, Bhandari S, Won Y, Goutam U, Kanth Pulicherla K, Son YO, et al. High-throughput
576 sequencing technologies in the detection of livestock pathogens, diagnosis, and zoonotic surveillance.
577 Comput Struct Biotechnol J. 2022;20:5378-92.
578 12. Ko KKK, Chng KR, Nagarajan N. Metagenomics-enabled microbial surveillance. Nat Microbiol.
579 2022;7(4):486-96.
580 13. Iwu-Jaja C, Ndlovu NL, Rachida S, Yousif M, Taukobong S, Macheke M, et al. The role of
581 wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence from
582 South Africa supports sentinel site surveillance to guide public health decision-making. Sci Total Environ.
583 2023;903:165817.
584 14. GenomeTrakr-protocols-wastewater [Available from: https://www.protocols.io/file-
585 manager/682C9E830C0A11EC806D0A58A9FEAC02.
586 15. Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing
587 of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods
588 Protoc. 2020;5(1):bpaa014.
589 16. Swift BioSciences. "NEW- Swift Normalase™ Amplicon SARS-CoV-2 Panels." [Available from:
590 https://swiftbiosci.com/swift-normalase-amplicon-sars-cov-2-panels-3/.
591 17. VarSkip Multiplex PCR Designs for SARS-CoV-2 Sequencing. 2021. Reprint, New England Biolabs
592 Inc., 2021 [Available from: https://github.com/nebiolabs/VarSkip.
593 18. The Pango nomenclature is being used by researchers and public health agencies worldwide to
594 track the transmission and spread of SARS-CoV-2, including variants of concern. [Available from:
595 https://cov-lineages.org/.

19. Cui Y, Peng L, Hu Y, Lai HJ. Assessing the Reproducibility of Microbiome Measurements Based on Concordance Correlation Coefficients. J R Stat Soc Ser C Appl Stat. 2021;70(4):1027-48.
20. Palarea-Albaladejo J M-FJ. zCompositions- R package for multivariate imputation of left-censored data under a compositional approach. Chemometrics and Intelligent Laboratory Systems. 2015;143:85-96.
21. Timme RE, Woods J, Jones JL, Calci KR, Rodriguez R, Barnes C, et al. SARS-CoV-2 wastewater variant surveillance: pandemic response leveraging FDA's GenomeTrakr network. medRxiv. 2024:2024.01.10.24301101.
22. Bivins A, Kaya D, Bibby K, Simpson SL, Bustin SA, Shanks OC, et al. Variability in RT-qPCR assay parameters indicates unreliable SARS-CoV-2 RNA quantification for wastewater surveillance. Water Res. 2021;203:117516.
23. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines (Basel). 2021;9(10).
24. Iwamoto R, Yamaguchi K, Katayama K, Ando H, Setsukinai KI, Kobayashi H, et al. Identification of SARS-CoV-2 variants in wastewater using targeted amplicon sequencing during a low COVID-19 prevalence period in Japan. Sci Total Environ. 2023;887:163706.
25. ARTIC primer revamping [Available from: https://community.artic.network/c/laboratory/6.
26. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. 2020.
27. Paola Cristina Resende FCM, Sunando Roy, Luciana Appolinario, Allison Fabri, Joilson Xavier, Kathryn Harris, Aline Rocha Matos, Braulia Caetano, Maria Orgeswalska, Milene Miranda, Cristiana Garcia, André Abreu, Rachel Williams, Judith Breuer, Marilda M Siqueira. SARS-CoV-2 Genomes Recovered by Long Amplicon Tiling Multiplex Approach Using Nanopore Sequencing and Applicable to Other Sequencing Platform. BioRXIV. 2020.

Acknowledgements

We gratefully acknowledge the wastewater treatment plant for collecting samples for this study and sharing it with us. We acknowledge Dr. Leena Malayil and Dr. Amy Sapkota, School of Public Health, University of Maryland for introducing us to the WWTP for sample collection. We acknowledge CovidTrakr working groups at the Center for Food Safety and Applied Nutrition (CFSAN) for discussion that facilitated this manuscript. We also acknowledge the support of CFSAN high performance computing engineers G. Engelbach, J. Payne, K. Konganti, and M. Hammond. We acknowledge all data contributors for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is partly based.

Author Contributions

PR performed sample collection, lab experiments, data interpretations and wrote and edited the manuscript. TK developed C-WAP and performed data analysis and interpretation. PR, AW, CG and MH conceived and designed the study and performed laboratory experiments. KJ performed lab experiments and data interpretation. CB, TP, MB, ST and RT developed the dashboard. EB retrieved samples from WWTP. BT performed concordant correlation coefficient analysis. JA, DE, JP and HR performed data analysis. All authors reviewed and edited the manuscript and approved the final version.

Funding

This project was supported in part by funding from the American Rescue Plan Act of 2021. Jasmine Amirzadegan, Candace Hope Bias, Kathryn Judy, and Tammy Walsky's participation was supported by an appointment to the Research Participation Program at the U.S. Food and Drug Administration administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. Tunc Kayikcioglu and Dietrich EppSchmidt received financial support from Joint Institute for Food Safety and Applied Nutrition (JIFSAN), University of Maryland as part of financial assistance award U01FD001418 funded by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Table 1: QC metrics monitored for data submission and further analysis.

Schematic Fig1 : Weekly collection and processing of composite samples: From February 23rd through June 30, 2022, daily composite samples were pooled into a single sample of two biological replicates per

654 week. Each biological replicate was then split into three 40mL technical replicates, resulting in six
655 samples per week that was taken into further processing.

656 Figure 1: Flowchart of wastewater processing and analysis workflow: Wastewater samples collected
657 from the treatment plant were pooled by week and the total nucleic acid (TNA) was extracted using
658 Promega Enviro TNA kit. Genomic DNA was digested with ezDNase prior to cDNA synthesis using
659 Superscript IV Reverse Transcriptase. The cDNA was amplified using either NEBNext VarSkip Short (VSS)
660 primers for long-read (~550bp) sequencing on the Oxford Nanopore Technologies GridION or QIAseq
661 DIRECT (QIAseq) primers for short-read (~250bp) sequencing on the Illumina MiSeq. All sequences were
662 processed through the CFSAN Wastewater Analysis Pipeline, producing a report that included QC
663 metrics as well as relative abundance of variants. Sequences that pass QC are submitted to NCBI and the
664 variant calls were published in the FDA dashboard.

665 Figure 2: SARS-CoV-2 viral load and relationship to clinical cases: The relationship of wastewater-based
666 surveillance burden estimations and actual clinical reporting, with clinical data plotted against the viral
667 genome copies/L, over time. The rolling 7-day average of new clinical SARS-CoV-2 cases (black) in the
668 sewer shed graphed alongside the viral load over time (blue), calculated from RT-qPCR on raw
669 wastewater and 24h composite samples taken from the wastewater treatment plant. Number of cases is
670 indicated on the right-hand axis, while genome copies/L is marked on the left.

671 Figure 3: Percentage of aligned reads vs. wastewater viral load : Weekly average percent reads aligned
672 to the SC2 genome (black) and the weekly average SC2 viral load (gc/L) detected by RT-qPCR from
673 wastewater (orange). Sequencing runs/data from both enrichment panels (NEB VSS and QIAseq DIRECT,
674 n=364) included in the averaging to calculate the weekly percent reads aligned were quality filtered to <
675 20% sites with 0x coverage and < 40% sites covered <10x after alignment.

Figure 4: Coverage depth vs coverage breadth: Sequencing depth versus breadth of the SARS-CoV-2 genome covered for each amplicon kit and every month of wastewater surveillance. Any point along a given line indicates the percentage (breadth, y-axis) of the SARS-CoV-2 genome covered to the corresponding sequence depth (x-axis) for that single sample. The green bar on the first panel of January 2022, shows an ideal sequencing run with maximum depth covering the entire genome. Each line indicates one sequenced sample that resulted in <20% sites along the genome covered 0x and <40% sites covered <10x after alignment.

Figure 5: Genome coverage across ORF1ab, S, M, and N genes of SC2 genome: Genome coverage by amplicon kit for key genes used to detect SARS-CoV-2 variants from January through June 2022. The averaged number of under-covered (fewer than 10 quality-filtered and trimmed reads aligned) for each gene and amplicon kit over time is indicated in red, with worse coverage (poorer sequencing performance) in lighter colors.

Figure 6: Concordant Correlation Coefficient (CCC) analysis: concordant correlation coefficient analysis on the variant calling performance of Freyja and kallisto on eleven samples between May and June 2022 sequenced with both NEB VarSkip Short and QIAseq DIRECT primers. A CCC of +1 indicates perfect agreement, -1 indicates perfect disagreement, and 0 indicates no agreement.

Figure 7: Proportional abundance of SARS-CoV-2 variants detected over time: Proportional abundance of SARS-CoV-2 variants detected over time, as identified by the Freyja variant caller on sequence data from both the enrichment panels (NEB VSS and QIAseq DIRECT, n=364). Variants always detected in a proportion of less than 1% were grouped together as “Others <1%”.

Figure 8: Verification of the BA.2 variant detection in wastewater on January 29th, 2022, using both the enrichment panel (NEB VSS and QIAseq DIRECT): 8A. Proportional abundance of SARS-CoV-2 variants by day, January 27th – February 1st 2022. 8b. Frequency of BA.1 and BA.2 –characteristic mutations over

699 four dates. Mutations typically incompatible with BA.1 (teal), characteristic for BA.1 or BA.2 (purple),
700 and diagnostic for BA.2 (green, in a highlighted box) are shown at their location in the SARS-CoV-2
701 genome. All depicted mutations are significant (p-value < 0.05), but smaller circles indicate lower p-
702 values. BA.2 was detected in the bottom three date panels.

703 Supplementary table1: Sample collection and pooling strategies employed in this study.

704 Supplementary table 2: Characteristic mutation table by C-WAP.

705 Supplementary table 3:Rolling 7 day average of new cases for zip codes monitored in this study along
706 with the wastewater viral load (gc/L).

707 Supplementary Figure 1: SC2 population trend by sampling date using both the enrichment panel and
708 Freyja as the variant caller.

709 Supplementary reports: Example reports of the comprehensive analysis produced by C-WAP.






Percent reads aligned to SC2 genome
75
50
25
0
2e+05
1e+05
0e+00
SC2 genome copies/L
Jan 2022
Feb 2022
Mar 2022
Apr 2022
Jun 2022
Jul 2022
Collection date


January
February
March
April
May
June
Breadth
Depth
100
75
50
25
0
1
10
100
1000
10000
Amplicon kit
QIAseq
VarSkip Short




AMPLICONPANEL
NEB VSS v1a
QIAseq DIRECT
-0.25
0.00
0.25
0.50
0.75
CCC with 95% CI


Proportional abundance (%)
100
75
50
25
0
15 Jan 2022
15 Feb 2022
15 Mar 2022
15 Apr 2022
15 May 2022
15 Jun 2022
Month
SC-2 variants
Omicron: BA.1
Omicron: BA.2
Omicron: BA.2.12
Omicron: BA.3
Omicron: BA.4
Omicron: BA.4.6
Omicron: BA.5
Other B.*
Other B.1.*
Omicron: B.1.1.529
A Sublineages
X*: Recombinants
Others < 1%


2022-01-27
2022-01-28
2022-01-29
2022-01-30
2022-01-31
2022-02-01
Proportional abundance(%)
100
75
50
25
0
Sublineage groups
Variants and Sublineages
Omicron: BA.1
Omicron: BA.2
Omicron: BA.2.12
Other B.*
Other B.1.*
Omicron: B.1.1.529
X*: Recombinants
Others < 1%
NA


2022-01-28
2022-01-29
2022-01-31
2022-03-30
Mutation frequency
1.00
0.75
0.50
0.25
0.00
0
10000
20000
30000
Mutation compatibility with BA.1 and BA.2
BA.1 or BA.2
Incompatible with BA.1
p-value
0.0000
0.0025
0.0050
0.0075
BA2_diagnostic
BA.2 diagnostic mutation
Other mutation
5' UTR
ORF1ab
S
ORF3a
E
M
ORF6
ORF7a
ORF7b
ORF8
N
ORF10
3' UTR
Genome position, bases



Sample collection

Sample processing

Total nucleic acid extraction

Short and long read sequencing

Custom analysis using C-WAP

NCBI submission



Public health dashboard

Variant detection



Mutation detection

Mutation name	Compatible lineages
NUC C241T	B.1.427
DEL 372 1	None found
ORF1AB S135R	BA.2, BA.3, BA.4, BA.5
NUC C835T	B.1.617.3
DEL 1001 1	None found
ORF1AB T842I	BA.2, BA.4, BA.5

Sequencing Quality metrics



SARS-CoV-2 reads per sample (%Covid hits)



How deeply did we sequence the SARS-CoV-2 genome?



How evenly did we cover the genome?

52 hrs

76 hrs


WEEKLY COLLECTION &
PROCESSING OF COMPOSITES
FEB 23, 2022 – JUNE 28, 2022
BIO. REP 1
TECH. REP 1
TECH. REP 2
TECH. REP 3
POOL
DAY 1
DAY 2
DAY 3
DAY 4
DAY 5
DAY 6
DAY 7
REP. 1
REP. 2
POOL
BIO. REP 2
TECH. REP 1
TECH REP 2
TECH REP 3